Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)
- Status
- COMPLETED
- Phase
- PHASE1
Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
- Status
- COMPLETED
- Phase
- PHASE1
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)
- Status
- COMPLETED
- Phase
- PHASE2
Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)
- Status
- COMPLETED
- Phase
- PHASE1